OBJECTIVE: Leptin signaling is important in the establishment of pregnancy. We sought to determine if single nucleotide polymorphisms (SNPs) in the leptin and leptin receptor genes are associated with idiopathic recurrent pregnancy loss (RPL). STUDY DESIGN: We conducted a case-control study with cases defined as women with idiopathic RPL and controls as parous women without pregnancy losses. A total of 99 cases and 108 controls were genotyped for the leptin ( À 2548 G/A) SNP and the leptin receptor A223G SNP. Genotype and allele frequencies were compared between cases and controls using w 2 test. RESULT: In this population, there was no significant difference in the genotype or allele frequencies for the leptin ( À 2548 G/A) or leptin receptor A223G SNPs between women with idiopathic RPL and controls. CONCLUSION: Although leptin signaling is critical to many aspects of reproduction, the maternal leptin and leptin receptor SNPs evaluated in this study are unlikely to have a clinically meaningful role in RPL.
INTRODUCTION
Pregnancy loss is a common problem, affecting 10 to 15% of clinically recognized pregnancies in the United States. 1, 2 It is estimated that 0.5 to 1% of couples suffer from recurrent pregnancy loss (RPL), commonly defined as at least two or three pregnancy losses. 2 Although RPL has been associated with genetic syndromes, 3 reproductive tract malformations, 4 maternal disease, 5 infections, 6 immunologic disorders 7 and thrombophilias, 8 an underlying cause remains undefined in 40 to 50% of the cases. 9 Leptin is a hormone that functions as a signal to the central nervous system regarding peripheral energy stores, but also has a critical role in reproduction. 10 Leptin is secreted primarily by adipocytes, and circulating levels are usually directly proportional to an individual's amount of adipose tissue. Human obesity is considered to be a 'leptin-resistant' state, as the hormone should typically function to reduce appetite and food intake. 11 Animal and human studies indicate that alterations in leptin signaling may increase the risk for pregnancy loss. Leptin-deficient mice are obese, insulin resistant and have diminished fertility, all of which are corrected with exogenous leptin administration. 12 Crosstalk between leptin and the leptin receptor may be critical to the establishment of early pregnancy. In mice, interference with leptin signaling results in a reduction in the number of implantation sites. 13 Leptin levels are also associated with embryo quality and in vitro fertilization success. 14, 15 Several groups have investigated whether maternal serum leptin levels in early pregnancy can predict miscarriage, and results have been mixed. 16, 17 However, the measurement of serum leptin levels is limited by variation with the time of day and proximity to food intake. We hypothesized that genetic variants in the leptin receptor (LEPR) or leptin (LEP) genes would confer an increased risk for RPL.
Single nucleotide polymorphisms (SNPs) in the LEPR gene have been investigated in relation to various conditions including breast cancer, obesity and severe preeclampsia. [18] [19] [20] One of the most commonly studied SNPs in the leptin receptor is the A223G polymorphism, which occurs within one of the two putative leptin-binding regions and may be associated with impaired signaling capacity. 21 The G allele has been associated with an increased risk for severe preeclampsia. 20 As preeclampsia involves impaired trophoblast invasion of the maternal spiral arteries, the pathogenesis of some cases of preeclampsia may be similar to early pregnancy loss in terms of impaired placentation.
The ( À 2548 G/A) SNP in the LEP gene has been associated with an increased risk of breast and prostate cancer. 18, 22 In addition, the A allele is associated with a two-fold increase in leptin secretion from adipocytes as compared with the G allele. 23 Using an established data and tissue bank, we sought to determine whether the A223G SNP in the LEPR gene and/or the ( À 2548 G/A) SNP in the LEP gene are associated with idiopathic RPL.
METHODS

Subjects
We conducted a retrospective case-control study. Cases were defined as women with a history of at least two pregnancy losses at o20 weeks of gestation, with no identified cause. Losses confirmed to be secondary to cervical insufficiency did not qualify women for inclusion as a case. Diagnostic evaluation for causes of RPL was at the discretion of the physician, but women identified to have a uterine anomaly, antiphospholipid antibodies, inherited thrombophilia or abnormal parental karyotype, were excluded. Cases had previously given consent for participation in a RPL Database and Tissue Bank. This consent includes participation in future studies using stored samples. Women with RPL who 1 Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA; 2 Maternal-Fetal Medicine, Intermountain Healthcare, Salt Lake City, UT, USA and are seen at the University of Utah or Intermountain Healthcare are recruited for participation in this Database and Tissue Bank and Institutional Review Board approval was obtained for this specific study from both of these institutions.
Controls were defined as women with a history of at least two live births and no history of pregnancy losses. Controls were identified from the University of Utah's Universal Sample Database and Tissue Bank, a collection of information and biological samples from consenting patients presenting for labor and delivery, with storage for future analyses. Controls were matched 1:1 to cases by race/ethnicity and maternal age (within 5 years).
Clinical data, including body mass index (BMI) and confirmation of any diagnostic evaluations for causes of RPL, were abstracted from the patients' medical charts.
Genetic analyses
Maternal DNA was isolated from stored buffy coats using the PureGene DNA Purification System (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols. Concentration and yield were determined using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Samples were adjusted to a standard concentration prior to genotyping.
Samples were genotyped for the LEPR A223G and the LEP ( À 2548 G/A) SNPs using TaqMan allelic discrimination chemistry (Applied Biosystems, Foster City, CA, USA), with validated primers and manufacturers protocols. Specifically, 6 ng of DNA was included in a 5 ml reaction with a final concentration of 1 Â Taqman genotyping master mix and 0.5 Â Taqman genotyping assay mix. The genotyping assay mix is specific to each SNP and contains both primers and allele-specific probes. After a 10-min initial denaturation at 95 1C, samples were amplified for 45 cycles of 95 1C for 15 s and 60 1C for 1 min on an ABI 9700 thermal cycler. Genotypes were detected through end point analysis after the PCR reaction. Genotyping software (SDS V2.3, Applied Biosystems) was used to automatically generate cluster plots and determine sample genotypes. Genotypes were also manually verified. Quality control metrics, including deviation from HardyWeinberg equilibrium were accessed prior to the final genotype call.
Statistical analyses
Clinical characteristics were compared between groups using Student's t-test or w 2 test as appropriate. Chi-square was used to evaluate for differences in the frequency of genotypes for each SNP between cases and controls. To evaluate for interactions between the LEP and LEPR SNPs in association with RPL, logistic regression models were constructed, containing interaction terms between the genotypes for the two polymorphisms. Allele frequencies were calculated for each SNP and were compared using w 2 test, with odds ratios for RPL calculated (major allele as referent). Analysis was performed with SAS software (version 9.2; SAS Institute Cary, NC, USA). A P-value o0.05 was considered statistically significant.
RESULTS
Altogether, 114 cases met the inclusion criteria and had available DNA. Controls were matched 1:1 with cases based on race and age. A total of 207 women had DNA that was successfully genotyped (99 cases and 108 controls) for the LEPR A223G and the LEP ( À 2548 G/A) SNPs. 
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Leptin and recurrent pregnancy loss JR Chin et al and LEPR SNP genotypes in association with RPL were all non-significant (P40.05).
The results were similar when the analysis was restricted to the 54 cases with X4 losses (data not shown).
DISCUSSION
In our study population, neither the LEPR A223G SNP nor the LEP ( À 2548 G/A) SNP was associated with idiopathic RPL. Although the available number of RPL cases limits the power of our study, our results indicate that there is not a strong or clinically meaningful association between these SNPs and RPL. Post hoc sample size calculations indicate that over 1000 cases would be needed to provide 80% power to detect a significant difference (alpha 0.05) in allele frequencies between cases and controls.
Since it's discovery in 1994 as a satiety signal to the central nervous system, leptin has received attention for the important role it has in reproduction. Leptin receptor expression has been identified at multiple points along the human hypothalamicpituitary-gonadal axis, as well as in the endometrium, 10 where receptor levels increase in the luteal phase of the menstrual cycle. 24 The human blastocyst expresses leptin, 24 and maternal serum leptin levels vary during the menstrual cycle, with the highest levels noted during the luteal phase. 25 Leptin is produced in abundance by the placenta 26 and stimulates matrix metalloproteinases, which are involved in trophoblast invasion. 27 Other investigators have studied whether SNPs in the LEPR or LEP genes might be associated with pregnancy complications, such as preeclampsia. Sugathadasa et al. 28 found that for the LEP ( À 2548 G/A) SNP, the A allele conferred a relative risk of 1.67 (95% CI 1.28-2.18) for preeclampsia or pregnancy-induced hypertension. Preeclampsia was also associated with a higher circulating leptin concentration, a finding noted by others. 29 It has been hypothesized that elevated leptin levels in the setting of preeclampsia may be the result of an upregulation of placental leptin production in response to hypoxia. 30 Rigo et al. 20 reported that for the LEPR A223G SNP, women with the G allele had nearly double the risk of developing severe preeclampsia compared with women who were homozygous for the A allele. However, others have been unable to confirm the association between LEP and LEPR SNPs, and preeclampsia. 31 A small number of studies have examined how maternal leptin levels might relate to the risk of miscarriage. Laird et al. 16, 17 measured leptin and leptin-binding activity in 53 women with a history of RPL at two times during the first trimester of pregnancy. Women who subsequently miscarried had significantly lower plasma leptin concentrations (but no difference in leptin-binding activity) than those that went on to have a term birth. However, it is impossible to determine from such studies whether abnormal leptin levels are actually causative of pregnancy loss or simply the result of an already failing pregnancy.
Our study is timely in that over one-third of all women in the United States are now obese (BMI X30 kg m À 2 ), 32 with approximately one-in-five being obese at the onset of pregnancy. 33 Obese women are at increased risk for miscarriage, with their losses more likely to be non-aneuploid. 34, 35 However, the mechanisms by which maternal obesity increases the risk for pregnancy loss are not well understood. An attractive theory is that genetic variants in the LEP and/or LEPR genes might increase the risk for both obesity and RPL. However, there is a general lack of evidence for an association between LEP and LEPR SNPs, and obesity. Hoffstedt et al. 23, 36, 37 found that among 39 women, leptin secretion from adipose tissue was twice as high among those with the AA genotype for the LEP ( À 2548 G/A) SNP as compared with those with a GA or GG genotype. How this finding relates to the risk for obesity is difficult to determine, however, as all the women in that study were non-obese. Similar to the study of RPL, linking specific SNPs to a risk for obesity is challenging due to the fact that the pathogenesis of the disease is so complex.
Our study was not designed to examine causes for RPL specifically among obese women. It remains possible that alterations in leptin signaling, either from higher circulating maternal levels related to increased adipose tissue or genetic variation, may be a contributing cause in this group. Future studies should examine potential causes for RPL specifically among the subset of obese women.
Despite the critical role that leptin appears to have in the establishment of pregnancy, to our knowledge this is the first study to explore whether SNPs in the LEP and/or LEPR genes are associated with RPL. Given that there are likely to be multiple contributing factors to RPL, we were able to attain relative phenotypic purity with 490% of our cases having three or more pregnancy losses and our controls having no history of pregnancy losses.
This study demonstrates the challenges in identifying genetic risks for complex diseases such as RPL. Although we excluded women with identified causes for RPL, not all women had a comprehensive evaluation. However, this reflects the reality of clinical practice and the expense of testing. Furthermore, there are certainly causes of RPL that are yet to be discovered. Another limitation is that we included women with RPL who had a history of live births (although the majority had none or only one live birth), and women with a range of pre-embryonic, embryonic and fetal losses. Heuser et al. 38 found that among women with idiopathic RPL, losses tend to recur around the same gestational age, suggesting the involvement of distinct causative pathways for losses at different stages. It is possible that genetic variants in the LEP or LEPR genes only confer an increased risk for loss at a specific gestational age. Our sample size limits us from exploring this question further. Finally, we were unable to determine the paternal or embryonic/fetal genotypes. Given the crosstalk in leptin signaling that occurs between the blastocyst and endometrium, paternal and embryonic/fetal genetic variants may interact in important ways with maternal factors to contribute to pregnancy failure. The study of genetic contributors to complex diseases is rapidly advancing. Future studies of genetic risk for RPL should move beyond candidate gene studies and the study of single SNPs to utilize methods such as whole-genome sequencing. 
